FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4225248411> ?p ?o ?g. }

• W4225248411 abstract "You have accessJournal of UrologyCME1 May 2022MP03-07 IMPACT OF PRIOR INTRAVESICAL BACILLUS CALMETTE-GUERIN THERAPY FOR NON-MUSCLE INVASIVE BLADDER CANCER ON THE EFFICACY OF PEMBROLIZUMAB IN PATIENTS WITH METASTATIC UROTHELIAL CARCINOMA Rikiya Taoka, Takashi Kobayashi, Yu Hidaka, Hiroyasu Abe, Satoshi Morita, Osamu Ogawa, Hiroyuki Nishiyama, Hiroshi Kitamura, and Mikio Sugimoto Rikiya TaokaRikiya Taoka More articles by this author , Takashi KobayashiTakashi Kobayashi More articles by this author , Yu HidakaYu Hidaka More articles by this author , Hiroyasu AbeHiroyasu Abe More articles by this author , Satoshi MoritaSatoshi Morita More articles by this author , Osamu OgawaOsamu Ogawa More articles by this author , Hiroyuki NishiyamaHiroyuki Nishiyama More articles by this author , Hiroshi KitamuraHiroshi Kitamura More articles by this author , and Mikio SugimotoMikio Sugimoto More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002515.07AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: This study aimed to determine whether prior intravesical bacillus Calmette-Guerin (BCG) therapy for non-muscle invasive bladder cancer (NMIBC) affects the treatment outcomes of pembrolizumab in patients with urothelial carcinoma (UC). METHODS: In a multicenter retrospective study conducted under the Japan Urological Oncology Group framework, the clinicopathological data of 755 patients with metastatic, chemo-resistant UC who received pembrolizumab were retrospectively reviewed. The best overall response and overall survival (OS) from the initiation of pembrolizumab were analyzed concerning the BCG usage using propensity score matching (PSM). The propensity score was estimated using a logistic regression model with four covariates, namely, PS, metastatic site, pretreatment Hb level, and NLR. (Kobayashi T, et al. Cancer Sci. 2021). RESULTS: A total of 155 (20.5%) patients had a history of NMIBC treatment, of which 97 (12.8%) had received intravesical BCG therapy. When compared to patients without a NMIBC history (median 9.97 months), the OS in patients with a NMIBC history but not BCG (14.49 months, HR 0.68 [0.45–1.12], P=0.061) or those with a NMIBC history and BCG (12.13 months, HR 0.87 [0.64–1.17], P=0.356) were not significantly different. This tendency was robust after 1:1 or 1:2 PSMs. The objective response rate (ORR, 32.1% vs. 27.5%, P=0.606) and disease control rate (DCR, 56.6% vs. 45.1%, P=0.241) of the 58 patients with a NMIBC history but not BCG did not differ from those of 58 matched patients without a NMIBC history. The ORR in BCG-treated patients was significantly lower than that in those without a NMIBC history (19.8% vs. 33.3%, P=0.042), whereas DCR between the two groups did not differ significantly (55.8% vs. 54.4%, P=0.855). CONCLUSIONS: Our risk-adjusted analyses revealed that intravesical BCG therapy did not affect the treatment outcomes of pembrolizumab in metastatic UC patients. Source of Funding: None © 2022 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 207Issue Supplement 5May 2022Page: e22 Advertisement Copyright & Permissions© 2022 by American Urological Association Education and Research, Inc.MetricsAuthor Information Rikiya Taoka More articles by this author Takashi Kobayashi More articles by this author Yu Hidaka More articles by this author Hiroyasu Abe More articles by this author Satoshi Morita More articles by this author Osamu Ogawa More articles by this author Hiroyuki Nishiyama More articles by this author Hiroshi Kitamura More articles by this author Mikio Sugimoto More articles by this author Expand All Advertisement PDF downloadLoading ..." @default.
• W4225248411 created "2022-05-04" @default.
• W4225248411 creator A5015926039 @default.
• W4225248411 creator A5027603182 @default.
• W4225248411 creator A5038206081 @default.
• W4225248411 creator A5043392549 @default.
• W4225248411 creator A5058573237 @default.
• W4225248411 creator A5071117344 @default.
• W4225248411 creator A5071455815 @default.
• W4225248411 creator A5077840773 @default.
• W4225248411 creator A5083025134 @default.
• W4225248411 date "2022-05-01" @default.
• W4225248411 modified "2023-09-26" @default.
• W4225248411 title "MP03-07 IMPACT OF PRIOR INTRAVESICAL BACILLUS CALMETTE-GUERIN THERAPY FOR NON-MUSCLE INVASIVE BLADDER CANCER ON THE EFFICACY OF PEMBROLIZUMAB IN PATIENTS WITH METASTATIC UROTHELIAL CARCINOMA" @default.
• W4225248411 doi "https://doi.org/10.1097/ju.0000000000002515.07" @default.
• W4225248411 hasPublicationYear "2022" @default.
• W4225248411 type Work @default.
• W4225248411 citedByCount "0" @default.
• W4225248411 crossrefType "journal-article" @default.
• W4225248411 hasAuthorship W4225248411A5015926039 @default.
• W4225248411 hasAuthorship W4225248411A5027603182 @default.
• W4225248411 hasAuthorship W4225248411A5038206081 @default.
• W4225248411 hasAuthorship W4225248411A5043392549 @default.
• W4225248411 hasAuthorship W4225248411A5058573237 @default.
• W4225248411 hasAuthorship W4225248411A5071117344 @default.
• W4225248411 hasAuthorship W4225248411A5071455815 @default.
• W4225248411 hasAuthorship W4225248411A5077840773 @default.
• W4225248411 hasAuthorship W4225248411A5083025134 @default.
• W4225248411 hasConcept C121608353 @default.
• W4225248411 hasConcept C126322002 @default.
• W4225248411 hasConcept C126894567 @default.
• W4225248411 hasConcept C143998085 @default.
• W4225248411 hasConcept C2777546739 @default.
• W4225248411 hasConcept C2777701055 @default.
• W4225248411 hasConcept C2780057760 @default.
• W4225248411 hasConcept C2780352672 @default.
• W4225248411 hasConcept C2911057145 @default.
• W4225248411 hasConcept C3019882237 @default.
• W4225248411 hasConcept C71924100 @default.
• W4225248411 hasConceptScore W4225248411C121608353 @default.
• W4225248411 hasConceptScore W4225248411C126322002 @default.
• W4225248411 hasConceptScore W4225248411C126894567 @default.
• W4225248411 hasConceptScore W4225248411C143998085 @default.
• W4225248411 hasConceptScore W4225248411C2777546739 @default.
• W4225248411 hasConceptScore W4225248411C2777701055 @default.
• W4225248411 hasConceptScore W4225248411C2780057760 @default.
• W4225248411 hasConceptScore W4225248411C2780352672 @default.
• W4225248411 hasConceptScore W4225248411C2911057145 @default.
• W4225248411 hasConceptScore W4225248411C3019882237 @default.
• W4225248411 hasConceptScore W4225248411C71924100 @default.
• W4225248411 hasIssue "Supplement 5" @default.
• W4225248411 hasLocation W42252484111 @default.
• W4225248411 hasOpenAccess W4225248411 @default.
• W4225248411 hasPrimaryLocation W42252484111 @default.
• W4225248411 hasRelatedWork W2754795980 @default.
• W4225248411 hasRelatedWork W2780238408 @default.
• W4225248411 hasRelatedWork W2899953288 @default.
• W4225248411 hasRelatedWork W2904110710 @default.
• W4225248411 hasRelatedWork W3028814175 @default.
• W4225248411 hasRelatedWork W3033877262 @default.
• W4225248411 hasRelatedWork W3134635137 @default.
• W4225248411 hasRelatedWork W3135333393 @default.
• W4225248411 hasRelatedWork W4254895532 @default.
• W4225248411 hasRelatedWork W4353086468 @default.
• W4225248411 hasVolume "207" @default.
• W4225248411 isParatext "false" @default.
• W4225248411 isRetracted "false" @default.
• W4225248411 workType "article" @default.